Latest Trials

EudraCT Number: 2004-005012-80 Sponsor Protocol Number: S245.4007 Start Date: 2005-03-03
Sponsor Name: Solvay Pharmaceuticals GmbH
Full Title: Double-blind, multicenter, randomized, placebo-controlled, parallel-group study to investigate the effect of Creon 25 000 Minimicrospheres on body mass index (BMI) in patients after gastrectomy.
Medical condition: Patients atleast 18 years old with total or subtotal gastrektomy.
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FI (Ongoing)
Trial results: (No results available)
EudraCT Number: 2004-002344-99 Sponsor Protocol Number: SKY0402-C-203 Start Date: 2005-03-03
Sponsor Name: SkyePharma, Inc.
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Escalating/De-Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sustained-Release Encapsulated Bupivacaine (SKY0402) ...
Medical condition: Pain following bunionectomy
Disease: Version SOC Term Classification Code Term Level
6.0 10006586 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: (No results available)
EudraCT Number: 2004-004823-36 Sponsor Protocol Number: AZ1-2004 Start Date: 2005-03-03
Sponsor Name: daacro - diagnostic assessment and clinical research organization
Full Title: Effects of Alprazolam and Flupentixol on endocrine, autonomic and psychological parameters in the Trier Social Stress Test (TSST)
Medical condition: 69 healthy male subjects, age 18-45 undergo a laboratory stress test (TSST)
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male
Trial protocol: DE (Completed)
Trial results: (No results available)
EudraCT Number: 2004-004392-11 Sponsor Protocol Number: ULg_GBM_04/1 Start Date: 2005-03-03
Sponsor Name: Centre Hospitalier Universitaire de Liege
Full Title: Human phase 1/2 clinical study of the safety and efficacy of sulfasalazine as a therapy for recurrent or progressing high grade gliomas.
Medical condition: Recurrent or progressive high grade glioma, including gliobastoma, anaplastic astrocytoma and oligo-astrocytoma.
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2004-004928-12 Sponsor Protocol Number: VICER1 Start Date: 2005-03-03
Sponsor Name: INO Therapeutics AB
Full Title: A pilot, unicenter, prospective, aleatorized, with parallel groups, controlled and open to evaluate the efficacy of the Nitric Oxide for Inhalation in the prevention of reperfusion in pulmonary donor
Medical condition: pulmonary graft dysfunction
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: ES (Completed)
Trial results: View results
EudraCT Number: 2004-001332-23 Sponsor Protocol Number: EORTC Study 08013 Start Date: 2005-03-03
Sponsor Name: European Organisation for Research and Treatment of Cancer
Full Title: Phase II Study with Gefitinib (sequentially) following Gemcitabine/Cisplatin as induction regimen for patients with stage IIIA N2 NSCLC.
Medical condition: Advanced Non Small-Cell Lung Carcinoma
Disease: Version SOC Term Classification Code Term Level
7.0 10061873 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BE (Completed)
Trial results: View results
EudraCT Number: 2004-000167-95 Sponsor Protocol Number: Protocol F1J-MC-HMDI Start Date: 2005-03-03
Sponsor Name: Eli Lilly and Company Limited
Full Title: Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
Medical condition: Major Depressive Disorder
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SE (Completed) IT (Completed) DE (Completed)
Trial results: View results
EudraCT Number: 2005-000127-42 Sponsor Protocol Number: NRSily1 Start Date: 2005-03-03
Sponsor Name: Medical University of Vienna
Full Title: Non Responder- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF SILYMARIN IN ADDITION TO COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND RIBAVIRIN IN PATIENTS WI...
Medical condition: HCV-patients, who have not responded to a previous therapy with INF or PEG-INF +/- Ribavirin.
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: AT (Completed)
Trial results: (No results available)
EudraCT Number: 2004-004206-25 Sponsor Protocol Number: 1839IL/0711 Start Date: 2005-03-02
Sponsor Name: AstraZeneca AB
Full Title: A PHASE II MULTICENTRE RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ZD1839 (IRESSA TM) (250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN CHEMOTHERAP...
Medical condition: Non-Small Cell Lung Cancer
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IE (Completed) CZ (Completed)
Trial results: View results
EudraCT Number: 2004-002103-32 Sponsor Protocol Number: 50-03B Start Date: 2005-03-02
Sponsor Name: GELA-Recherche Clinique
Full Title: Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma,...
Medical condition: CD 20 positive diffuse large B cell lymphoma
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: IE (Completed)
Trial results: View results

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe